Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

被引：13

作者：

Zeidan, Amer M. ^{[1
,2
]}

Borate, Uma ^{[3
]}

Pollyea, Daniel A. ^{[4
]}

Brunner, Andrew M. ^{[5
]}

Roncolato, Fernando ^{[6
]}

Garcia, Jacqueline S. ^{[7
]}

Filshie, Robin J. ^{[8
]}

Odenike, Olatoyosi ^{[9
,10
]}

Watson, Anne-Marie ^{[11
]}

Krishnadasan, Ravi ^{[12
]}

Bajel, Ashish ^{[13
,14
]}

Naqvi, Kiran ^{[15
]}

Zha, Jiuhong ^{[16
]}

Hogdal, Leah ^{[16
]}

Zhou, Ying ^{[16
]}

Hoffman, David ^{[16
]}

Kye, Steve ^{[16
]}

Garcia-Manero, Guillermo ^{[17
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA

[4] Univ Colorado, Dept Hematol, Aurora, CO USA

[5] Massachusetts Gen Hosp, Ctr Leukemia, Boston, MA 02114 USA

[6] Univ New South Wales, Dept Hematol, Sydney, NSW, Australia

[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[8] St Vincents Hosp Melbourne, Dept Hematol, Melbourne, Vic, Australia

[9] Univ Chicago Med, Chicago, IL USA

[10] Comprehens Canc Ctr, Chicago, IL USA

[11] Liverpool Hosp, Dept Haematol, Liverpool, Merseyside, Australia

[12] Univ Arizona, Canc Ctr, Tucson, AZ USA

[13] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic, Australia

[14] Royal Melbourne Hosp, Melbourne, Vic, Australia

[15] Genentech Inc, San Francisco, CA 94080 USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145646

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

537

引用

页数：6

共 50 条

[31] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure
Duong, Vu H.
Lin, Karen
Reljic, Tea
Kumar, Ambuj
Al Ali, Najla H.
Lancet, Jeffrey E.
List, Alan F.
Komrokji, Rami S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 711 - 715
[32] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
Al Ali, Najla
Sallman, David
Chan, Onyee
Padron, Eric
Sweet, Kendra
Kuykendall, Andrew
Lancet, Jeffrey
Komrokji, Rami
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
[33] LOW DOSE VENETOCLAX/CYTARABINE THERAPY IS EFFECTIVE AND SAFE IN RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME PATIENTS FAILED PREVIOUS HYPOMETHYLATING AGENT'S TREATMENT
Ruda, M. F.
Pilo, F.
Caocci, G.
Pettinau, M.
Romani, C.
Garau, P.
La Nasa, G.
HAEMATOLOGICA, 2022, 107 : 64 - 64
[34] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
Yang, Lin
Banerji, Versha
LANCET ONCOLOGY, 2024, 25 (04): : 413 - 414
[35] Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens
Miller, Jenn
Shannon, Lindsey
Finch, Amanda
Altman, Jessica K.
Wojenski, Daniel
BLOOD, 2020, 136
[36] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
Short, Nicholas J.
Daver, Naval
Dinardo, Courtney D.
Kadia, Tapan
Nasr, Lewis F.
Macaron, Walid
Yilmaz, Musa
Borthakur, Gautam
Montalban-Bravo, Guillermo
Garcia-Manero, Guillermo
Issa, Ghayas C.
Chien, Kelly S.
Jabbour, Elias
Nasnas, Cedric
Huang, Xuelin
Qiao, Wei
Matthews, Jairo
Stojanik, Christopher J.
Patel, Keyur P.
Abramova, Regina
Thankachan, Jennifer
Konopleva, Marina
Kantarjian, Hagop
Ravandi, Farhad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
[37] Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
Prebet, Thomas
Braun, Thorsten
Beyne-Rauzy, Odile
Dreyfus, Francois
Stammatoullas, Aspasia
Wattel, Eric
Ame, Shanti
Raffoux, Emmanuel
Delaunay, Jacques
Charbonnier, Aude
Ades, Lionel
Fenaux, Pierre
Vey, Norbert
LEUKEMIA RESEARCH, 2014, 38 (01) : 29 - 33
[38] An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes
Pleyer, Lisa
Sekeres, Mikkael A.
LANCET HAEMATOLOGY, 2022, 9 (10): : E714 - E716
[39] Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome
Lin, Che-Hung
Yeh, Su-Peng
Lin, Tze-Yi
ANNALS OF HEMATOLOGY, 2015, 94 (11) : 1925 - 1926
[40] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Garcia, Jacqueline S.
Platzbecker, Uwe
Odenike, Olatoyosi
Fleming, Shaun
Fong, Chun Yew
Cook, Rachel
Jacoby, Meagan
Nowak, Daniel
Chyla, Brenda
Zhou, Ying
Ku, Grace
Potluri, Jalaja
Garcia-Manero, Guillermo
BLOOD, 2023, 142

← 1 2 3 4 5 →